寻找尼莫
高级会员
- 注册
- 2015-11-07
- 消息
- 1,187
- 荣誉分数
- 480
- 声望点数
- 193
Gilead今天公布了人民的希望三期中症治疗试验结果，10天疗程无明显疗效。股票大跌，前面几位认死理的想想再怎么帮它辩解吧。
Gilead Falls After Phase 3 Remdesivir 10-Day Trial Failed To Reach Significance
by Tyler Durden
Mon, 06/01/2020 - 08:45
TwitterFacebookRedditEmailPrint
One week after the New England Journal of Medicine found mixed results in its pivotal study of Remdesivir in covid-19 patients which "found no marked benefit from remdesivir for those who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine" and only "significantly helped those on supplemental oxygen", concluding that "given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient", moments ago Gilead announced its own results from a Phase 3 trial of Remdesivir in patients with moderate Covid-19 and which, similarly, appeared to disappoint because while the press release was quick to point out that "patients in the 5-day remdesivir treatment group were 65% more likely to have clinical improvement at Day 11 compared with those in the standard of care group," this was not relevant, and what did matter is that "the odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care... failed to reach statistical significance."
www.zerohedge.com
Gilead Falls After Phase 3 Remdesivir 10-Day Trial Failed To Reach Significance
by Tyler Durden
Mon, 06/01/2020 - 08:45
TwitterFacebookRedditEmailPrint
One week after the New England Journal of Medicine found mixed results in its pivotal study of Remdesivir in covid-19 patients which "found no marked benefit from remdesivir for those who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine" and only "significantly helped those on supplemental oxygen", concluding that "given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient", moments ago Gilead announced its own results from a Phase 3 trial of Remdesivir in patients with moderate Covid-19 and which, similarly, appeared to disappoint because while the press release was quick to point out that "patients in the 5-day remdesivir treatment group were 65% more likely to have clinical improvement at Day 11 compared with those in the standard of care group," this was not relevant, and what did matter is that "the odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care... failed to reach statistical significance."
ZeroHedge
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
www.zerohedge.com
